HIKAL · Hikal Ltd · Biotechnology & Drugs
HIKAL · Hikal Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
15.9% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹403 Cr
Revenue YoY
PAT YoY
+67.0%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.2
P/S (TTM)
1.6
Sector P/E
36.3
Dividend yield
+0.3%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| HIKAL (this stock) | Not meaningful (earnings negative over the last 12 months) | 2.2 | -1.9% | -2.8% | 0.57 | +0.3% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 3q
MF
5.92% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-09-07 | HIKAL | 6792472 | 6 | WEAK | BULK |
| 2026-09-03 | HIKAL | 2467791 | 3 | WEAK | BULK |
News timeline
- lowindian-share-tips.com· 30 Jul 2026, 09:26 amHas Hikal Limited Entered A Fresh Medium-Term Uptrend?
Concalls & investor presentations
AI-generatedKey takeaway: Hikal Limited held its Q1 FY27 earnings conference call on August 6, 2026, where management provided updates on the company's financial and operational performance for the quarter ended June 30, 2026. Management reported a revenue of Rs 403 crores and an EBITDA margin of 9.2%. The company highlighted its recent EcoVadis Gold Medal Rating, placing it in the top 5% of companies assessed for sustainability. The Pharmaceutical business showed year-on-year growth despite a planned shutdown for U.S. FDA remediation. Management noted a gradual recovery in the Crop Protection business, although pricing pressures remained due to excess supply from China. The Animal Health segment continued to perform well, with strong demand and new project validations. Management discussed ongoing investments in capacity and R&D, aiming for long-term growth across its divisions. The call concluded with management expressing confidence in the company's strategic direction and commitment to sustainable growth.
Management emphasized achievements and growth potential across various business segments.
Sourced from an exchange-filed transcript, dated 12 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Hikal Limited's earnings conference call for Q3 and the nine months ended December 31, 2025, highlighted a return to operational profitability with consolidated revenue of INR494 crores and EBITDA of INR83 crores for the quarter. Management noted a steady recovery in the global chemical and life sciences industry, although challenges such as pricing pressures from overcapacity in the Crop Protection segment persist. The company reported a significant improvement in the Pharmaceutical segment, with revenues of INR337 crores and an EBIT margin of 12.3%. Management emphasized ongoing investments in R&D and infrastructure, particularly in high-potency laboratories and a new pilot plant. The Crop Protection segment generated revenues of INR157 crores, facing margin pressures. Management expressed confidence in the company's strategic positioning for sustainable growth, particularly in the Animal Health and Personal Care segments, and announced an interim dividend of INR0.2 per share.
Management emphasized recovery and strategic growth opportunities despite ongoing challenges.
Sourced from an exchange-filed transcript, dated 17 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Hikal Limited's investor presentation for the quarter and nine months ended December 31, 2025, reported a return to positive operational performance following a regulatory cycle that began in early 2025. Management indicated that the Pharmaceutical business saw a significant recovery, with consolidated revenue for Q3 at ₹494 crore and EBITDA at ₹83 crore. The presentation highlighted that the Pharmaceutical segment generated ₹337 crore in revenue with an EBIT margin of 12.3%, while the Crop Protection segment reported ₹157 crore in revenue with a 3% EBIT margin. Management noted that strategic investments made over the past year are now operational, enhancing capabilities in high-entry-barrier segments. The document also mentioned disciplined cost management and a strong balance sheet, with a debt-equity ratio of 0.58x. Overall, the presentation emphasized improving operating momentum and stabilization across key segments.
Management emphasized a recovery in operational performance and improvements across key business segments.
Sourced from an exchange-filed presentation, dated 11 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedHikal Limited's FY2025-26 annual report highlights strategic investments in pharmaceutical and crop protection capabilities, including advanced R&D infrastructure and CDMO services. The company emphasized sustainability and ESG initiatives, achieving an EcoVadis Gold Rating. Despite challenges like US FDA compliance issues and pricing pressures, Hikal focused on capacity expansion, regulatory upgrades, and diversifying its supply chain to enhance resilience. The report noted a decline in financial metrics like PAT and EBITDA, attributed to exceptional charges and operational constraints.
- Strategic investments in pharmaceutical R&D and CDMO capabilities to enhance complex chemistry execution
- Commitment to sustainability and ESG, reflected in EcoVadis Gold Rating and Zero Liquid Discharge systems
- Focus on capacity expansion and regulatory upgrades to support future growth in Pharmaceuticals, Animal Health, and Personal Care
Key takeaway: Hikal is prioritizing long-term growth through strategic investments in R&D, sustainability, and capacity expansion, despite current financial challenges and regulatory hurdles.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (2 items); Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
2 occurrencesRecent (last 12 months)
The auditor has expressed a concern that the matter described in the Emphasis of Matter may have an adverse effect on the functioning of the Company.
Earlier (1-3 years ago)
The auditor has expressed a concern that the matter described in the Emphasis of Matter may have an adverse effect on the functioning of the Group.
Regulatory Action
2 occurrencesRecent (last 12 months)
The US FDA regulatory action impacted the company's profits and led to asset impairment at the Panoli facility.
Earlier (1-3 years ago)
The company has faced regulatory non-compliance issues related to PCB consent and hazardous waste guidelines, leading to the implementation of corrective measures such as an online monitoring system and compliance audits.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
As at 31 March 2026, the company has contingent liabilities related to direct and indirect taxes, including Income Taxes, Excise Duty, Central Sales Tax, Value Added Tax, and Goods and Service Tax, with ₹195 million for which favourable orders were received by the company.
Earlier (1-3 years ago)
The company has a contingent liability of ₹6 million recoverable from a director due to excess remuneration paid in violation of section 197 of the Companies Act, 2013.
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
The company made a related-party transaction by contributing to an entity where certain directors of the Holding Company are directors, with an amount of 7.50 million rupees.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has outstanding income tax dues of 162.30 K in million under the Income Tax Act, 1961, with disputes pending before the Bombay High Court relating to FY 2002-04, FY 2006-07, FY 2009-10, and FY 2010-11.
Earlier (1-3 years ago)
The company has unpaid tax dues under the Income Tax Act, Goods and Services Tax, and Central Excise Act, with amounts totaling Rs. 162.30 million, Rs. 228.87 million, and Rs. 65.98 million respectively, pending in various forums including the Bombay High Court and Commissioner of Income Tax (Appeals).
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
3.37% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).